KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gross Profit (2016 - 2025)

Historic Gross Profit for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $997.2 million.

  • Jazz Pharmaceuticals' Gross Profit rose 571.03% to $997.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 731.46%. This contributed to the annual value of $3.6 billion for FY2024, which is 660.88% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Gross Profit stood at $997.2 million, which was up 571.03% from $929.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Gross Profit ranged from a high of $997.2 million in Q3 2025 and a low of $567.4 million during Q1 2021
  • In the last 5 years, Jazz Pharmaceuticals' Gross Profit had a median value of $807.8 million in 2022 and averaged $817.8 million.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 2782.93% in 2022, then soared by 169.83% in 2025.
  • Jazz Pharmaceuticals' Gross Profit (Quarter) stood at $760.6 million in 2021, then grew by 5.81% to $804.8 million in 2022, then increased by 12.42% to $904.7 million in 2023, then grew by 6.05% to $959.5 million in 2024, then rose by 3.94% to $997.2 million in 2025.
  • Its Gross Profit was $997.2 million in Q3 2025, compared to $929.4 million in Q2 2025 and $959.5 million in Q4 2024.